8 completed, 8 recruiting, 5 active not recruiting, 4 not yet recruiting. 34 Phase 2, 5 Phase 1.
Follow Cystectomy: new trials by email Literature Review of Cystectomy trials Research Report on Cystectomy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Enfortumab vedotin, Pembrolizumab, Cisplatin - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 70 | 2026-10-16 | 2026-11-02 |
| Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy Neoadjuvant Chemotherapy, Partial cystectomy with Extended pelvic lymph node dissection, Adjuvant systemic therapy - Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2026-09-01 | 2026-09-24 | |
| The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment - Bladder Cancer | Phase 2 | Not yet recruiting | Chiti Arturo | 262 | 2026-09-01 | 2025-12-02 |
| A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab - Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-09-01 | 2026-09-03 | |
| Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC Enfortumab Vedotin, Pembrolizumab, Radiation - Urothelial Bladder Cancer | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 56 | 2026-09-01 | 2026-06-25 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma Radical cystectomy - Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma | Phase 2 | Recruiting | Yale University | 32 | 2025-11-26 | 2026-10-07 |
| Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Disitamab Vedotin Injection, Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, Radical Cystectomy with Pelvic Lymph Node Dissection - Bladder Cancer, Muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2025-04-30 | 2025-05-04 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Reproductive organ sparing radical cystectomy, Radical cystectomy - Urothelial Carcinoma Bladder | Phase 2 | Recruiting | University of Florida | 127 | 2024-08-30 | 2026-09-09 |
| RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients DisitamabVedotinForIicction Toripalimab - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 55 | 2024-06-19 | 2026-10-08 |
| Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma Adebrelimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder, Bladder Cancer | Phase 2 | Recruiting | RenJi Hospital | 22 | 2023-11-16 | 2025-12-08 |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan - Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 4 | 2023-06-15 | 2026-04-27 |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Atezolizumab, Carboplatin, Cisplatin - Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 63 | 2022-06-27 | 2026-06-25 |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion - Urothelial Carcinoma Bladder | Phase 2 | Active not recruiting | The Methodist Hospital Research Institute | 33 | 2022-02-15 | 2025-10-24 |
| Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer Cisplatin, Doxorubicin, Methotrexate - Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | Phase 2 | Completed | University of Washington | 17 | 2020-11-24 | 2025-09-18 |
| Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Pembrolizumab, Entinostat, Procedure/Surgery - Bladder Cancer | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-09-23 | 2026-10-23 |
| Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer Cabozantinib, Atezolizumab, Cystectomy - Bladder Cancer | Phase 2 | Active not recruiting | Deepak Kilari | 46 | 2020-05-21 | 2024-12-04 |
| Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Carboplatin, Cisplatin, Cystectomy - Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma | Phase 2 | Terminated | Stanford University | 7 | 2019-04-10 | 2023-09-11 |
Showing 20 of 34. Sign in to see all of them.
Urinary Bladder Neoplasms (26) · Carcinoma, Transitional Cell (2) · Cone Dystrophy 3 (1) · Endometriosis (1) · Urinary Bladder Diseases (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
University of Washington (5) · Memorial Sloan Kettering Cancer Center (3) · Radiation Therapy Oncology Group (2) · UNC Lineberger Comprehensive Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Case Comprehensive Cancer Center (1) · Chiti Arturo (1) · Deepak Kilari (1) · Eli Lilly and Company (1) · Fox Chase Cancer Center (1) · Jules Bordet Institute (1) · Ligartis GmbH (1) · Noah Hahn, M.D. (1) · Plasma Surgical Inc (1) · RenJi Hospital (1)
United States (23) · China (3) · France (2) · Germany (2) · Belgium (1) · Canada (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Petros Grivas (2) · Abai Xu, doctor (1) · Anthony L. Zietman, MD (1) · Cheryl T. Lee, MD (1) · Chin-Lee Wu, MD, PhD (1) · Daniel Gorovets, MD (1) · David C Smith, MD (1) · Dean Bajorin, MD (1) · Deepak Kilari, MD (1) · Fed Ghali, MD (1) · Gopa Iyer, MD (1) · Horace Roman, MD, PhD (1) · Jean Hoffman-Censits, MD (1) · John J. Coen, MD (1)
PMID 20089114, PMID 21205754, PMID 23228446, PMID 23706253, PMID 23823157, PMID 25366678, PMID 25392649, PMID 31900121, PMID 34856936, PMID 35703113, PMID 40329651, PMID 40413024
2016 (1), P30CA015704 (1), P30CA016086 (1), U10CA180821 (1)